Priorities for the Next FDA Commissioner: Trust, Food Policy, and Drug Reforms Under Trump Administration

The Search for a New FDA Leader

The Trump administration is moving swiftly to find a successor for Marty Makary, who resigned as FDA commissioner on Tuesday. The goal is to identify a candidate who can mend relationships with agency staff, prioritize food safety and nutrition policies, and sustain momentum in drug-approval process improvements, according to an administration official familiar with the plans.

The official, speaking on condition of anonymity, said the search is expected to take place over the next several weeks. Despite speculation among industry lobbyists about potential contenders, no formal shortlist has been compiled yet. The White House is casting a wide net to attract qualified leaders who align with the administration's health agenda.

Key Priorities for the Agency's Next Head

Rebuilding Internal Trust

A top concern is restoring confidence among FDA employees, many of whom have faced morale challenges during recent leadership transitions and public scrutiny. The next commissioner must demonstrate a commitment to transparent communication, scientific integrity, and valuing career staff expertise. Trust is seen as essential for effective regulatory oversight and retaining top talent.

Advancing Food Policy

Food safety and nutrition regulation is another central focus. The administration wants a leader who will vigorously pursue updates to food labeling, tackle issues like heavy metals in baby food, and modernize the FDA's approach to dietary supplements and novel food ingredients. The goal is to align agency actions with public health needs while reducing unnecessary burdens on the industry.

Continuing Drug-Approval Reforms

Under Makary, the FDA accelerated approvals for breakthrough therapies and streamlined generic drug reviews. The next commissioner is expected to build on those reforms, including further use of real-world evidence, adaptive trial designs, and expedited pathways for rare diseases. However, balancing speed with safety and efficacy standards remains a delicate challenge.

Timeline and Challenges Ahead

Although the administration is eager to fill the post quickly, the process will inevitably stretch over months. The Senate calendar is limited, and confirmation hearings are also pending for Erica Schwartz at the CDC and Nicole Saphier as Surgeon General. These competing priorities mean the FDA may not have a confirmed commissioner until late spring or early summer.

In the interim, Kyle Diamantas, who previously led the FDA's food center, is expected to continue as acting commissioner. Some observers note that Diamantas could still be in the role when the November midterm elections arrive, underscoring the slow pace of political appointments.

To navigate these hurdles, the administration is focusing on candidates with strong bipartisan appeal, regulatory experience, and a vision for modernizing the FDA without sacrificing its public health mission. The official emphasized that the search will be thorough, as the stakes for American consumers and the pharmaceutical industry are high.

As the process unfolds, stakeholders will be watching closely. The next FDA leader will shape policies on everything from obesity drugs and food additives to gene therapies and medical devices. For more on the transition, see the search overview and priority areas.